Maven Securities’s Atara Biotherapeutics ATRA Stock Holding History

Maven Securities’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,800	Closed	-$926K	–	573
2020 Q3	$926K	Buy	+2,800	New	+$954K	0.08%	261

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Maven Securities's ATRA Position: Q4 2020 in Review

Maven Securities sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 2,800 shares — an estimated $926K sold.

Maven Securities first reported a position in ATRA in Q3 2020 and held it in 1 quarter. The position peaked at $926K in Q3 2020. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

Maven Securities reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
Maven Securities sold 2,800 Atara Biotherapeutics shares in Q4 2020, an estimated $926K.
Maven Securities first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 1 quarter.
Maven Securities's Atara Biotherapeutics position peaked at $926K in Q3 2020.
148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.